Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.38 |
| ▸ | RET | P07949 | 3/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140809 | 0.88 | KDM2B (0.45) | HRH3KDM2BIRAK4CYP3A4CYP2C9 | |
| SCHEMBL4135879 | 0.88 | ACVR1 (0.42) | HRH3KDM2BKCNH2DGAT1RET | |
| SCHEMBL4935121 | 0.85 | HRH3 (0.41) | HRH3KDM2BKCNH2IRAK4CYP3A4 | |
| SCHEMBL4136957 | 0.84 | HRH3 (0.47) | HRH3KDM2BKCNH2IRAK4CYP3A4 | |
| SCHEMBL4135823 | 0.82 | ACVR1 (0.41) | HRH3KDM2BDGAT1RETCYP3A4 | |
| SCHEMBL4136820 | 0.82 | HRH3 (0.37) | HRH3KDM2BKCNH2 | |
| SCHEMBL4136921 | 0.81 | KDM2B (0.44) | HRH3KDM2BRETIRAK4CYP3A4 | |
| SCHEMBL4935533 | 0.81 | KDM2B (0.43) | HRH3KDM2BRETCYP3A4CYP2C9 | |
| SCHEMBL4136446 | 0.81 | HRH3 (0.54) | HRH3KCNH2DGAT1CYP3A4CYP2C9 | |
| SCHEMBL4130790 | 0.81 | GPR119 (0.47) | HRH3KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2021004-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2009-02-11 | — | — | EP | claimed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | claimed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | claimed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | HRH3, HRH4, HRH1 | HRH3 1/4885KDM2B 577/4885KCNH2 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.